Disclosures: Patrick INGILIZ: GILEAD: Speaking and Teaching, Abbvie: Speaking and Teaching, ViiV: Speaking and Teaching, Erwan Vo Quang: Nothing to Disclose, Maud Lemoine: Nothing to Disclose, Amie Ceesay: Nothing to Disclose, Gibril Ndow: Nothing to Disclose, Marie-Noelle Hilleret: Nothing to Disclose, Laure Bordy: Nothing to Disclose, Thomas Decaens: Nothing to Disclose, Anne-Laure Mazialivoua: Nothing to Disclose, Yusuke Shimakava: Nothing to Disclose, Alhagie Bakoteh: Nothing to Disclose, Jean-Michel Pawlotsky: Abbvie: Speaker, Abbott: Advisor, Gilead: Speaking and Teaching, GSK: Advisor, Isabelle CHEMIN: Nothing to Disclose, Stphane Chevaliez: Nothing to Disclose, Vincent Leroy: Nothing to Disclose 448 HEPATIC STEATOSIS IS ASSOCIATED WITH HBSAG CLEARANCE IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION Emin Bodakci 1 Saba Kiremiti 1 Serkan Duman 1 Zeynep Melekoglu Ellik 1 Mesut Gumussoy 1 Sevinc Tue Guvenir 1 Volkan YILMAZ 1 ramazan erdem er 1 Fatih Karakaya 1 Hale Gokcan 1 Atilla Elhan 1 Berna Savas 1 Ramazan Idilman 1 , 1 Ankara University Background: The present study aimed to determine the effect of hepatic steatosis detected by liver biopsy on HBsAg seroclearance and disease outcome in hepatitis B virus (HBV)-infected patients
Studies have pointed out that Treg cells have an indispensable part in the development of psoriasis (Hartwig et al., 2018)
Through an extensive review of current research and clinical endeavors, this chapter offers valuable insights into the evolving landscape of antioxidant therapy for cancer and T2D, underscoring the importance of redox modulation in disease management and prevention
You can get in touch with Ken at [email protected]
